**J. B. CHEMICALS & PHARMACEUTICALS LIMITED****REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:358

May 23, 2012

The Secretary,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub : Audited Financial Results for the year ended on March 31, 2012.

Enclosed please find the audited financial results of the company for the year ended on March 31, 2012. These financial results have been approved and taken on record by the board of directors at its meeting held today.


We request you to take the above on record.

Thanking you,

Yours faithfully,

M. C. Mehta

Company Secretary - General Manager



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS SAID, MUMBAI.


PHONE : 022 3045 1500 / 3045 1200

FAX : 022 2493 0534 / 2493 9633

<http://www.uniquepharma.com>

STATEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31/03/2012 PART I

Sr. No.	Particulars	3 Months ended			Year ended		(Rs. in lakhs)	
		31/03/2012	31/12/2011	31/03/2011	31/03/2012	31/03/2011	31/03/2012	31/03/2011
		Audited	Unaudited	Audited	Audited	Audited	Audited	Audited
1	Income from Operations							
	a. Net sales/Income from Operations (Net of excise duty)	14,800.02	14,955.91	17,889.06	63,577.48	78,757.94	77,619.17	87,168.09
	b. Other Operating Income	678.13	587.50	496.64	5,064.65	1,910.96	2,567.67	1,910.96
	Total Income from Operations (Net) (a+b)	15,478.15	15,543.41	18,385.70	68,642.13	80,668.90	80,186.84	89,079.05
2	Expenses							
	a. Cost of materials consumed	4,615.28	4,877.16	5,119.94	20,320.53	20,900.33	20,320.53	20,900.33
	b. Purchases of Stock-in-Trade	2,896.89	1,391.45	1,430.01	6,999.76	4,970.06	9,996.17	8,372.82
	c. Changes in inventories of finished goods work-in-progress and Stock-in-Trade	(1,709.68)	420.22	(1,243.43)	(547.18)	(1,564.67)	1,322.92	(1,875.96)
	d. Employees benefits expense	2,632.17	2,257.89	2,819.36	10,131.32	11,642.70	11,266.33	12,493.30
	e. Depreciation and amortization expense	532.46	562.94	567.78	2,230.40	2,265.08	2,242.46	2,278.78
	f. Exchange Fluctuation Suffered (Gain)/Loss	1,281.26	595.18	(200.10)	1,736.63	16.75	1,578.86	434.35
	g. Other Expenses	7,171.58	4,581.94	7,450.36	22,053.80	27,490.92	24,375.72	29,836.02
	Total Expenses	17,419.96	14,686.78	15,943.92	62,925.26	65,721.17	71,102.99	72,439.64
3	Profit/(Loss) from Operations before Other Income, Finance Cost and exceptional item (1-2)	(1,941.81)	856.63	2,441.78	5,716.87	14,947.73	9,083.85	16,639.41
4	Other Income	445.62	624.60	209.23	2,851.19	588.44	2,898.34	616.28
5	Profit/(Loss) from Ordinary Activities before Finance Cost and exceptional item (3+4)	(1,496.19)	1,481.23	2,651.01	8,568.06	15,536.17	11,982.19	17,255.69
6	Finance Cost	452.38	553.57	250.87	2,386.89	1,018.61	2,402.81	1,049.46
7	Profit/(Loss) from Ordinary Activities after Finance Cost but before Exchange Fluctuation Translation Gain / (Loss) (5-6)	(1,948.57)	927.66	2,400.14	6,181.17	14,517.56	9,579.38	16,206.23
8	Exchange Fluctuation Translation Gain / (Loss)	2,748.20	(2,758.23)	(617.02)	(1,318.27)	(422.22)	(1,294.51)	317.76
9	Profit from Ordinary Activities after Exchange Fluctuation Translation Gain / (Loss) but before Exceptional items (7+8)	799.63	(1,830.57)	1,783.12	4,862.90	14,095.34	8,284.87	16,523.99
10	Exceptional item	-	-	-	76,059.34	-	76,059.34	-
11	Profit/(Loss) from Ordinary Activities before Tax (9+10)	799.63	(1,830.57)	1,783.12	80,922.24	14,095.34	84,344.21	16,523.99
12	Tax expenses	(86.93)	(1,313.69)	306.57	16,652.30	2,275.88	16,553.33	2,591.62
13	Net Profit/(Loss) for the period from Ordinary Activities after Tax (11-12)	886.56	(516.88)	1,476.55	64,269.94	11,819.46	67,790.88	13,932.37
14	Paid Up Equity Share Capital (Face Value Rs.2/-)	1,694.15	1,694.15	1,690.34	1,694.15	1,690.34	1,694.15	1,690.34
15	Reserves excluding Revaluation Reserve	-	-	-	93,692.17	69,637.93	95,301.14	67,463.91
16	(i) Earning per share(EPS) (of Rs. 2/- each not annualised)							
	(1) Basic	1.05	(0.61)	1.75	75.95	14.00	80.11	16.50
	(2) Diluted	1.05	(0.61)	1.74	75.95	13.96	80.11	16.46



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

Sr. No	PART II - Particulars	3 Months ended			Year ended	
		31/03/2012	31/12/2011	31/03/2011	31/03/2012	31/03/2011
A	PARTICULARS OF SHAREHOLDING					
1	Public Shareholding					
	- Number of Shares	37,380,603	37,853,210	37,663,735	37,380,603	37,663,735
	- Percentage of shareholding	44.13	44.69	44.56	44.13	44.56
2	Promoters and Promoter Group Shareholding					
a)	Pledged/Encumbered	-	-	-	-	-
	- Number of Shares	-	-	-	-	-
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
b)	Non-encumbered					
	- Number of Shares	47,326,697	46,854,090	46,853,090	47,326,697	46,853,090
	- Percentage of shares (as a % of the shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	55.87	55.31	55.44	55.87	55.44

Particulars	3 Months ended 31.03.2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NH
Received during the quarter	3
Disposed of during the quarter	3
Remaining unresolved at the end of the quarter	NH

NOTES:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 23, 2012.
- The figures for the current year are strictly not comparable with the previous quarter/year consequent to sale of Russia - CIS OTC business undertaking during the year.
- The finance cost for the year ended on March 31, 2012, includes applicable foreign currency transaction/translation loss of Rs.1133.09 lakhs.
- The Board of Directors has recommended dividend of Re. 1.00 (50 %) per equity share of Rs.2/-. This together with dividend distribution tax will absorb Rs. 984.49 lakhs. The company has already paid Special Interim Dividend of Rs.40 per share during the year, which has absorbed Rs.393.78 crores including dividend distribution tax.
- The Exceptional Item relates to net income realised on sale of Russia - CIS OTC business undertaking during the year.
- The figures for the quarter ended on March 31, 2012 are the balancing figures between audited figures in respect of the full financial year and the published year-to-date figures upto the third quarter ended December 31, 2011.
- The company is engaged in a single segment of activity namely, "Pharmaceuticals".
- The statement of assets and liabilities as at March 31, 2012 is as under;
- Previous quarter's / period's figures have been regrouped / re-stated wherever necessary.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

http://www.uniquepharma.com

STANDALONE AND CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES
(Rs. in lakhs)


	Particulars	Standalone		Consolidated	
		AS AT 31.03.2012	AS AT 31.03.2011	AS AT 31.03.2012	AS AT 31.03.2011
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	a. Share Capital	1,694.15	1,690.34	1,694.15	1690.34
	b. Reserves and surplus	93,692.17	69,637.93	95,301.14	67463.91
	Sub Total of Shareholders' funds	95,386.32	71,328.27	96,995.29	69,154.25
2	Non-current liabilities				
	a. Long-term borrowings	1,152.17	1,202.94	1,254.50	1252.55
	b. Deferred tax liabilities (Net)	1,655.69	1,443.62	1,871.04	1626.91
	c. Long-term provisions	826.84	688.24	826.84	770.81
	Sub-Total - Non-current liabilities	3,634.70	3,334.80	3,952.38	3,650.27
3	Current liabilities				
	a. Short-term borrowings	5,522.65	13,336.37	5,522.65	13336.37
	b. Trade payables	3,353.77	4,435.81	3,709.02	5021.14
	c. Other current liabilities	7,669.74	5,569.87	7,874.96	6121.84
	d. Short-term provisions	1,704.53	2,721.62	1,725.59	2654.09
	Sub-Total - Current liabilities	18,250.69	26,063.67	18,832.22	27,133.44
	TOTAL-EQUITY AND LIABILITIES	117,271.71	100,726.74	119,779.89	99,937.96
B	ASSETS				
1	Non-current assets				
	a. Fixed assets	28,000.53	22,894.44	29,840.78	24524.15
	b. Goodwill on Consolidation	-	-	1,690.23	1690.23
	c. Non-current investments	3,878.98	4,224.21	299.61	393.64
	d. Long-term loans and advances	1,258.29	1,215.79	1,327.37	1269.75
	Sub-Total - Non-current assets	33,137.80	28,334.44	33,157.99	27,877.77
2	Current assets				
	a. Current Investments	29,892.18	8,104.63	29,892.18	8104.63
	b. Inventories	9,079.85	8,178.22	10,103.24	11167.01
	c. Trade receivables	13,120.82	38,545.42	13,605.11	34558.25
	d. Cash and cash equivalents	21,136.24	12,291.77	21,953.25	12688.57
	e. Short-term loans and advances	10,904.82	5,272.26	11,068.12	5541.73
	Sub-Total - Current assets	84,133.91	72,392.30	86,621.90	72,060.19
	Total-Assets	117,271.71	100,726.74	119,779.89	99,937.96

For J.B. Chemicals & Pharmaceuticals Ltd.

Place : Mumbai

Date : May 23, 2012

J.B. Mody
J.B. Mody
Chairman & Managing Director

**J. B. CHEMICALS & PHARMACEUTICALS LIMITED****REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022 2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:361

May 23, 2012

The Secretary,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Press Release

Enclosed is a press release we propose to issue on audited financial results for the year ended on March 31, 2012.

The said financial results were reviewed by the audit committee and approved by the board of directors at meeting held on May 23, 2012.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For J.B.Chemicals & Pharmaceuticals Ltd.

M. C. Mehta
Company Secretary - General Manager



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORS AID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, May 23, 2012:

Audited Financial Results for the year 2011-12

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its audited financial results for the financial year ended on March 31, 2012. The financial results for the quarter/year ended on March 31, 2012 are strictly not comparable with the results of the respective corresponding period in the previous year due to divestment of Russia-CIS OTC business during the year, which was significant part of the company's business. The highlights of these results are as under.


Financial Highlight for the year 2011-12:

Particulars	(Rs. in crores)			
	Standalone		Consolidated	
	2011-12	2010-11	2011-12	2010-11
Revenue from operations (Net)	686.42	806.69	801.87	890.79
Other Income	28.51	5.88	28.98	6.16
Total Revenue	714.93	812.57	830.85	896.95
Profit before exceptional item & tax	48.63	140.95	82.85	165.24
Exceptional item; Net income on sale of Russia-CIS OTC Business	760.59	---	760.59	---
Profit after tax	642.70	118.19	677.91	139.32
EPS (Rs.)	75.95	14.00	80.11	16.50
Book Value (Rs.)	112.61	84.40	114.51	81.82

The sales in domestic formulations remain the growth driver for the business. In that focus product group registered growth of 18%. This business has good growth potential and is poised to take advantage of growing domestic formulations market. The strategy is to focus on potential therapeutic groups coupled with enhanced penetration in Tier II cities and rural market, new product launches and increase in productivity. The growth is dependent on prescription generation, which is a slow process. However, the company is quite hopeful to achieve market growth.

The Rest of the world exports achieved growth of 37% with US market showing encouraging growth of 95%. The other markets such as Australia, Europe, Africa, Middle East and Asia too have shown good traction. The strategy in this business is to focus on contract manufacturing to build sustainable revenue stream with continued focus on niche branded generics. Encouraged by success in US, the company plans to file 8-10 ANDAs

✓



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAD, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022 2493 0534 / 2493 9633

<http://www.uniquepharma.com>

every year. The company has State-of-the-Art manufacturing infrastructure for preparation like tablets, injectables and lozenges and some of these facilities are approved by international health authorities such as US FDA, UK MHRA, TGA Australia, MCC South Africa and ANVISA Brazil. The company plans to leverage this strength by developing lucrative contract manufacturing business.

The company is building up marketing team in Russia-CIS for prescription products. This will help build prescription products demand, which will accrue in coming years.

Dividend:

The board of directors have recommended final dividend of Re 1 (50%) per equity share of FV 2. This together with dividend distribution tax will absorb Rs. 9.84 crores. During the year, the company also paid special interim dividend of Rs. 40 per equity share of FV 2. The outgo on account of special interim dividend including dividend distribution tax was Rs. 393.78 crores.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine, CIS countries and South Africa. The Company continues to invest in growing its share in the regulated markets in USA, Europe, Australia and Brazil. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMF's and ANDA's. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:


M.C. Mehta

Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- x --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.



J. B. CHEMICALS & PHARMACEUTICALS LIMITED

REGD. OFFICE:

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAID, MUMBAI.

PHONE : 022-3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM;SA:360

May 23, 2012

The Secretary,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Intimation of book closure

This is to inform you that the company has decided to close the register of members and the share transfer books, the details whereof are given hereunder:

Book Closure	Purpose
From 21/07/12 To <u>30/07/12</u> (both days inclusive)	Annual General Meeting and Declaration of dividend.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully,

M. C. Mehta

Company Secretary - General Manager

**J. B. CHEMICALS & PHARMACEUTICALS LIMITED****REGD. OFFICE:**

"NEELAM CENTRE", 'B' WING, 4TH FLR.,
HIND CYCLE ROAD, WORLI,
MUMBAI - 400 030.

GRAM : DOCTORSAID, MUMBAI.

PHONE : 022 3045 1500 / 3045 1200

FAX : 022-2493 0534 / 2493 9633

<http://www.uniquepharma.com>

StockExchange-NSE letters/MM:SA:359

May 23, 2012

The Secretary,
National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor,
Plot no.C/1, 'G' Block,
Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.

Stock Symbol: JBCHEPHARM

Dear Sir,


Sub : Intimation under clause 20 :Recommendation of dividend.

This is to inform you that the board of directors of the company at its meeting held today has recommended final dividend @ Re.1.00 (50%) per equity share of face value of Rs.2/-, for the financial year ended 2011-12. This together with dividend tax would absorb Rs. 984.49 lacs. The dividend if declared, will be paid/ despatched on August 9, 2012.

We request you to take the above on record.

Thanking you,

Yours faithfully,


M.C. Mehta

Company Secretary – General Manager